Paolo Tarantino is a leading researcher in the field of breast cancer, with over 50 papers published on the topic. He’s currently pursuing an advanced research fellowship at Dana-Farber Cancer Institute and at Harvard Medical School (Boston, MA). He is also concomitantly pursuing a PhD in clinical research at the University of Milan. His research focuses on the study of the HER2 oncoprotein, the emerging HER2-low subgroup of breast tumors and the development of novel antibody-drug conjugates to treat every subtype of breast cancer.
https://mbcbrainmets.org/wp-content/uploads/2023/08/Dr.-Paolo-Tarantino-Headshot.jpg 2000 2000 Lindsey Parker https://mbcbrainmets.org/wp-content/uploads/2021/10/brain-mets-logo-2.png Lindsey Parker2023-08-07 21:12:152023-08-09 20:14:31Dr. Paolo Tarantino
Defining HER2+ vs HER2 Disease
Trials: ADC'S in Active Brain Mets
HER2 Low Category for Brain Mets and LMD with T Dxd 1
What should a patient be asking their physician about HER2 Low and T Dxd
Potential Side Effects of T Dxd